Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1 Unknown 27 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Shanghai Simnova Biotechnology Co.,Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD19 chimeric antigen receptor(CAR)-modified NK cells(CAR-NK-CD19) in patients with relapsed or refractory hematological malignancies.

Timeline

Start: 2021-04-10
Primary completion: 2023-03-10
Completion: 2024-03-10

Publications

Background Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR-NK-CD19 Cells	Cell therapy	100000 cells	Other
Subject	CAR-NK-CD19 Cells	Cell therapy	1e+06 cells	Other
Subject	CAR-NK-CD19 Cells	Cell therapy	1e+07 cells	Other
Background	Cyclophosphamide	Other / unclassified	300 mg/kg	—
Background	Fludarabine	Small molecule	30 mg/kg	—

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Summary

Timeline

Publications

Drugs

Indications